Ignite Creation Date:
2025-12-24 @ 11:07 PM
Ignite Modification Date:
2026-01-01 @ 1:21 AM
Study NCT ID:
NCT04542369
Status:
UNKNOWN
Last Update Posted:
2023-05-03
First Post:
2020-09-02
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Pilot Study of PD-1inhibitor (Tislelizumab) Plus Chemotherapy as Neoadjuvant Therapy for Limited-Stage Small-Cell Lung Cancer
Sponsor:
Shanghai Pulmonary Hospital, Shanghai, China
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2021-05-01
Start Date Type:
ACTUAL
Primary Completion Date:
2023-12-31
Primary Completion Date Type:
ESTIMATED
Completion Date:
2025-11-30
Completion Date Type:
ESTIMATED
First Submit Date:
2020-09-02
First Submit QC Date:
None
Study First Post Date:
2020-09-09
Study First Post Date Type:
ACTUAL
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2023-05-01
Last Update Post Date:
2023-05-03
Last Update Post Date Type:
ACTUAL